Icovamenib met the primary endpoint in the COVALENT-111 trial, demonstrating a statistically significant, placebo-corrected reduction in HbA1c levels in type 2 diabetes patients.
Biomea Fusion is set to release topline results from its COVALENT-111 phase IIb trial of Icovamenib in approximately 200 patients with type 2 diabetes.
Biomea Fusion will host a conference call on December 17, 2024, to present topline results from the Phase II COVALENT-111 trial of icovamenib in type 2 diabetes.
The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.